Microbial Tryptamine as a Causative Cofactor of Incurable Cell Death Diseases of Unknown Etiology. The Cost of Related Healthcare in the US and Worldwide

Microbial Tryptamine as a Causative Cofactor of Incurable Cell Death Diseases of Unknown Etiology: The Cost of Related Healthcare in the US and Worldwide investigates microbial tryptamine and its role in a range of diseases, such as Alzheimer’s disease and Parkinson’s disease, while also examining the economic burden of these conditions on global healthcare systems. The book begins with an examination of microbial tryptamine’s significance across neurodegenerative diseases, cancers, and gastrointestinal conditions. It covers the implications of tryptamine in cell and organ transplantation, as well as the roles of diet and environment in tryptamine-induced disease progression. Additionally, the latest advances in treatment and prevention are considered. It then provides a critical analysis of expenditure on diseases related to tryptamine-induced cell toxicity and neurodegeneration, alongside an evaluation of current funding and market analysis. Following this, the author delves into research-related issues that may hinder biomedical progress, such as competition, plagiarism, and retractions of funded peer-reviewed articles. Collaboration between researchers and medical doctors is also examined. The book concludes with the author’s own personal narrative and recommendations, emphasizing the need for open discussions to drive urgent changes in biomedical research funding and review processes.

Part 1. Microbial tryptamine in diseases
1. Introduction: Contamination of food products with microbes producing cytotoxic tryptamine that induces gut dysbiosis
2. Differential abundance of tryptamine and related human gut microbial NQR sequence (ADAS) in cancers of gastrointestinal (GI) system and neurodegenerative diseases, spending budgets
3. Tryptamine in cell and organ transplantation
4. The roles of the diet and environment in the start and progression of diseases
5. Tryptamine-induced diseases: Future of biomedicine in saving lives by testing, preventing and treating the preventable/avoidable and modifiable medical conditions

Part 2. Expenditure and research funding
6. Expenditure on diseases related to tryptamine-induced cell toxicity and neurodegeneration
7. Funding of research projects and market analysis for diseases related to tryptamine

Part 3. Research-related issues interfering with the progress in the biomedical project
8. Competition, plagiarism and profit-driven motives in science
9. Massive retractions of funded articles is a symptom of serious failures in research funding
10. How do biology doctors and medical doctors clinicians collaborate?

Part 4. A personal narrative and conclusive remarks
11. About the Author
12. Conclusions

Authors

Elena L. Paley Adjunct Professor at Nova Southeastern University, FL,, USA. Dr. Paley is Cofounder of the nonprofit Stop Alzheimers Corp and Founder of Expert Biomed, Inc. She holds a PhD degree in biology with specialization in molecular biology from the Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences in the Laboratory of Lev L. Kisselev. Dr. Paley's research focuses mainly on protein biosynthesis in biology and diseases and is conducted in collaboration with Harvard University, Brandeis University, the University of Miami, Tel Aviv University, the Institut des Vaisseaux et du Sang (Paris, France), and the University of Texas at San Antonio. She is Adjunct Professor at Nova Southeastern University, FL, United States, and is inventor in patents issued and pending. Dr. Paley has previously published 4 books with Elsevier.

Table of Contents

Authors

Related Topics

Related Products

Diabetes and Neurodegeneration

Lysosomal Pathophysiology of Parkinson's Disease

Micro(nano)plastics in Organ Systems. Health Impacts, Challenges, and Future Prospects

Thematic Approaches to COVID-19

Features, Transmission, Detection, and Case Studies in COVID-19